Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells 21,700 Shares of Stock

Key Points

• Anne Lesage sold 21,700 shares on April 30 at an average price of $30.26 for $656,642 and has made multiple recent sales, reducing her stake by 27.77% to 56,450 shares valued at about $1.71 million.
• Shares traded down to $29.44 on heavy volume (512,191 vs. average 245,049) and sit within a 12‑month range of $14.59–$31.14.
• Pharvaris missed quarterly EPS estimates (loss of $0.84 vs. consensus of -$0.69), yet analysts maintain a "Moderate Buy" consensus with an average price target of $42.73.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) insider Anne Lesage sold 21,700 shares of the company's stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $30.26, for a total transaction of $656,642.00. Following the completion of the transaction, the insider owned 56,450 shares of the company's stock, valued at approximately $1,708,177. The trade was a 27.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Anne Lesage also recently made the following trade(s):

• On Wednesday, April 29th, Anne Lesage sold 3,700 shares of Pharvaris stock. The stock was sold at an average price of $30.08, for a total transaction of $111,296.00.
• On Thursday, April 30th, Anne Lesage sold 19,200 shares of Pharvaris stock. The stock was sold at an average price of $30.26, for a total transaction of $580,992.00.
• On Wednesday, April 22nd, Anne Lesage sold 7,000 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total transaction of $210,350.00.
• On Wednesday, April 22nd, Anne Lesage sold 7,500 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total transaction of $225,375.00.
• On Thursday, April 23rd, Anne Lesage sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total transaction of $3,003.00.

Pharvaris Stock Performance

Shares of PHVS traded down $1.57 during mid-day trading on Friday, reaching $29.44. The stock had a trading volume of 512,191 shares, compared to its average volume of 245,049. Pharvaris N.V. has a 12 month low of $14.59 and a 12 month high of $31.14. The business has a fifty day moving average of $27.62 and a 200 day moving average of $26.03.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.15). Equities analysts forecast that Pharvaris N.V. will post -3.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

Several institutional investors have recently bought and sold shares of PHVS. GF Fund Management CO. LTD. bought a new position in Pharvaris during the fourth quarter valued at $35,000. JPMorgan Chase & Co. lifted its position in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock valued at $59,000 after purchasing an additional 783 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Pharvaris during the third quarter valued at $75,000. Barclays PLC bought a new position in Pharvaris during the fourth quarter valued at $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Pharvaris during the fourth quarter valued at $86,000.

Wall Street Analyst Weigh In

Several research analysts have commented on PHVS shares. Wall Street Zen downgraded shares of Pharvaris from a "sell" rating to a "strong sell" rating in a report on Monday, April 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pharvaris in a report on Tuesday, April 21st. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 target price on shares of Pharvaris in a report on Tuesday, March 3rd. Citigroup reaffirmed a "buy" rating on shares of Pharvaris in a report on Wednesday, April 15th. Finally, Wolfe Research started coverage on Pharvaris in a report on Thursday, April 9th. They issued an "outperform" rating and a $42.00 target price on the stock. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $42.73.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.